|
WO2009137201A1
|
|
Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
|
|
CN101983062A
|
|
Abca-1 elevating compounds and the use thereof
|
|
WO2010002483A1
|
|
Optionally condensed dihydro pyridine, dihydropyrimidine and dihydro pyrane derivatives acting as late sodium channel blockers
|
|
CA2704981A1
|
|
Aldh-2 inhibitors in the treatment of psychiatric disorders
|
|
WO2009006580A1
|
|
Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
|
|
US2009081120A1
|
|
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
|
WO2009157938A1
|
|
A2b adenosine receptor antagonists for treating cancer
|
|
KR20100015685A
|
|
Ranolazine for enhancing insulin secretion
|
|
BRPI0809551A2
|
|
3-hydroquinazolin-4-ona derivatives for use as estearoil coa desaturase inhibitors
|
|
CA2682207A1
|
|
Quinazolinone derivatives as aldh-2 inhibitors
|
|
WO2008116083A1
|
|
Use of ranolazine for elevated brain-type natriuretic peptide
|
|
EP2117508A1
|
|
Intravenous solutions comprising ranolazine
|
|
WO2008101008A1
|
|
Use of ranolazine for the treatment of coronary microvascular diseases
|
|
WO2008101012A1
|
|
Use of ranolazine for the treatment of non-coronary microvascular diseases
|
|
WO2009088518A1
|
|
A2b adenosine receptor antagonists for the treatment of cancer
|
|
CA2673653A1
|
|
Myocardial perfusion imaging
|
|
CA2670651A1
|
|
Reduction of cardiovascular symptoms
|
|
CA2670788A1
|
|
A2a adenosine receptor antagonists
|
|
EP2131844A1
|
|
PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
|
CN101522676A
|
|
Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl CoA desaturase inhibitors
|
